Syncytin is involved in breast cancer-endothelial cell fusions
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Syncytin is involved in breast cancer-endothelial cell fusions. / Bjerregaard, Bolette; Holck, S.; Christensen, I.J.; Larsson, Lars-Inge.
I: Cellular and Molecular Life Sciences, Bind 63, Nr. 16, 2006, s. 1906-1911.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Syncytin is involved in breast cancer-endothelial cell fusions
AU - Bjerregaard, Bolette
AU - Holck, S.
AU - Christensen, I.J.
AU - Larsson, Lars-Inge
PY - 2006
Y1 - 2006
N2 - Cancer cells can fuse spontaneously with normal host cells, including endothelial cells, and such fusions may strongly modulate the biological behaviour of tumors. However, the underlying mechanisms are unknown. We now show that human breast cancer cell lines and 63 out of 165 (38%) breast cancer specimens express syncytin, an endogenous retroviral envelope protein, previously implicated in fusions between placental trophoblast cells. Additionally, endothelial and cancer cells are shown to express ASCT-2, a receptor for syncytin. Syncytin antisense treatment decreases syncytin expression and inhibits fusions between breast cancer cells and endothelial cells. Moreover, a syncytin inhibitory peptide also inhibits fusions between cancer and endothelial cells. These results are the first to show that syncytin is expressed by human cancer cells and is involved in cancer-endothelial cell fusions.
AB - Cancer cells can fuse spontaneously with normal host cells, including endothelial cells, and such fusions may strongly modulate the biological behaviour of tumors. However, the underlying mechanisms are unknown. We now show that human breast cancer cell lines and 63 out of 165 (38%) breast cancer specimens express syncytin, an endogenous retroviral envelope protein, previously implicated in fusions between placental trophoblast cells. Additionally, endothelial and cancer cells are shown to express ASCT-2, a receptor for syncytin. Syncytin antisense treatment decreases syncytin expression and inhibits fusions between breast cancer cells and endothelial cells. Moreover, a syncytin inhibitory peptide also inhibits fusions between cancer and endothelial cells. These results are the first to show that syncytin is expressed by human cancer cells and is involved in cancer-endothelial cell fusions.
KW - Former LIFE faculty
KW - Syncytin
KW - breast cancer
KW - endothelial cell
KW - fusion
KW - ASCT-2
U2 - 10.1007/s00018-006-6201-9
DO - 10.1007/s00018-006-6201-9
M3 - Journal article
VL - 63
SP - 1906
EP - 1911
JO - EXS
JF - EXS
SN - 1023-294X
IS - 16
ER -
ID: 8024861